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Background: Mixed ﬁbrolamellar hepatocellular carcinoma (mFL-HCC) is a rare liver tumor deﬁned by the presence
of both pure FL-HCC and conventional HCC components, represents up to 25% of cases of FL-HCC, and has been
associated with worse prognosis. Recent genomic characterization of pure FL-HCC identiﬁed a highly recurrent transcript
fusion (DNAJB1:PRKACA) not found in conventional HCC.
Patients and Methods: We performed exome and transcriptome sequencing of a case of mFL-HCC. A novel BAC-
capture approach was developed to identify a 400 kb deletion as the underlying genomic mechanism for a DNAJB1:
PRKACA fusion in this case. A sensitive Nanostring Elements assay was used to screen for this transcript fusion in a
second case of mFL-HCC, 112 additional HCC samples and 44 adjacent non-tumor liver samples.
*Correspondence to: Dr Obi L. Grifﬁth, McDonnell Genome Institute, Washington
University School of Medicine, 4444 Forest Park Blvd, St Louis, MO 63108, USA. E-mail:
obigrifﬁth@wustl.edu
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Results: We report the ﬁrst comprehensive genomic analysis of a case of mFL-HCC. No common HCC-associated
mutations were identiﬁed. The very low mutation rate of this case, large number of mostly single-copy, long-range copy
number variants, and high expression of ERBB2 were more consistent with previous reports of pure FL-HCC than
conventional HCC. In particular, the DNAJB1:PRKACA fusion transcript speciﬁcally associated with pure FL-HCC
was detected at very high expression levels. Subsequent analysis revealed the presence of this fusion in all primary and
metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC conﬁrmed
our ﬁnding that the fusion was detectable in conventional components. An expanded screen identiﬁed a third case of
fusion-positive HCC, which upon review, also had both conventional and ﬁbrolamellar features. This screen conﬁrmed the
absence of the fusion in all conventional HCC and adjacent non-tumor liver samples.
Conclusion: These results indicate that mFL-HCC is similar to pure FL-HCC at the genomic level and the DNAJB1:
PRKACA fusion can be used as a diagnostic tool for both pure and mFL-HCC.
Key words:mixed ﬁbrolamellar hepatocellular carcinoma, genome analysis, fusion transcript, DNAJB1:PRKACA
introduction
patient history
A woman in her 20s was diagnosed with mixed ﬁbrolamellar
and well-differentiated multifocal hepatocellular carcinoma
(mFL-HCC) (Figure 1). She had no underlying liver disease,
known cancer risk factors, or evidence of metastatic disease on
imaging. A complete timeline is provided in Figure 2 and more
detailed case presentation in supplementary Information,
available at Annals of Oncology online. She underwent a right
hepatic trisegmentectomy and portal vein thrombectomy for a
pT4bN0M0 tumor with three large tumor nodules (supplemen-
tary Figure S1, available at Annals of Oncology online).
Pathologic examination revealed that the largest nodule showed
typical histologic features of FL-HCC (PrimaryA1, A2), the
second largest showed only conventional HCC (PrimaryB1, B2)
and the smallest showed a mix of FL-HCC and conventional
HCC (PrimaryC1) (Figure 1A–C; supplementary Figure S2,
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Figure 1. Tumor pathology images showing mixed FL-HCC characteristics. The primary tumor resection included three tumor nodules exhibiting pathology
consistent with ﬁbrolamellar HCC, conventional HCC and mixed ﬁbrolamellar and conventional HCC. Representative images of H&E and immunohistochem-
ical staining for CK7 are shown for each nodule. (A) Fibrolamellar HCC with diffusely positive CK7 staining in the tumor cells. (B) Conventional HCC with
solid patterns primarily negative for CK7 staining with rare positive cells. (C) A region of the mixed nodule displaying conventional HCC with solid and
pseudoglandular patterns negative for CK7 staining. Metastatic tissue exhibiting features of ﬁbrolamellar HCC from (D) lung and (E) skin, resected 8 and
38 months after the primary tumor, respectively.
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available at Annals of Oncology online). Four months after
surgery, the patient developed metastatic disease and received
chemotherapy. At 8 months, surgical resection of metastatic
nodules in the abdomen and lungs (LungMet1-3; Figure 1D)
was performed, both of which had characteristics of FL-HCC on
pathologic evaluation. Three months later she began a 4-month
course of sorafenib for recurrent disease suspended during
stereotactic body radiotherapy (SBRT) to metastatic lung lesions
(supplementary Figure S3, available at Annals of Oncology
online). She continued to have progressive disease on imaging
and, over the next 5 months, she underwent surgical and locore-
gional therapy for recurrent disease in her torso. Subsequently,
she did well until about 32 months when she developed a
pulmonary metastasis and a solitary left temporal lobe brain me-
tastasis (BrainMet1.1, 1.2, 2) that was surgically resected followed
by SBRT. SBRT was also used for palliation of multiple recur-
rences. At month 38, symptomatic scalp (SkinMet1–2; Figure 1E)
and left deltoid masses were resected followed by treatment of a
left acetabulum lesion. Shortly before entering hospice, the patient
developed symptomatic progression and increased tumor burden
at multiple sites. For the last 28 months of her life, the patient
declined all systemic therapies other than alternative ones. At no
time did she develop recurrent liver lesions. She died about 44
months after the initial surgery and diagnosis.
Approximately 30 months into her cancer course, the patient
consented to genomic analyses to attempt to identify speciﬁc
targeted gene therapies. The BrainMet1 sample was chosen for
initial proﬁling and blood (BloodNorm) was collected for normal
comparator in genomic analyses. Targeted validation was per-
formed on additional RNA and DNA samples from the primary
tumor and additional metastases (Figure 1; supplementary
Table S1 and Methods, available at Annals of Oncology online).
Ultimately, the patient declined additional treatments suggested
by this analysis.
mixed and pure FL-HCC versus conventional HCC
FL-HCC is a rare liver tumor (0.02/100 000 age adjusted inci-
dence; ∼1% of HCC cases) [1] typically affecting adolescents
and young adults with no history of primary liver disease or cir-
rhosis [2]. mFL-HCC is deﬁned by the presence of features of
both conventional HCC and some but not all of the criteria for
pure FL-HCC [3] as initially deﬁned by Edmondson [4].
Patients with mFL-HCC may represent up to 25% of cases of
FL-HCC, tend to be older than pure FL-HCC (but still younger
than conventional HCC), and have been associated with worse
prognosis [3]. Recent studies have also revealed distinct tran-
scriptional signatures for pure and mixed FL-HCC [5].
Speciﬁcally, pure FL-HCC was characterized by overexpression
of ERBB2, genes involved in glycolysis, and several neuroendo-
crine genes compared with conventional HCC or mFL-HCC. As
such, mFL-HCC may represent a separate entity, or an
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Figure 2. A timeline depicts the clinical course of the patient in the months following resection of the primary mixed ﬁbrolamellar hepatocellular carcinoma.
Samples collected during the course of treatment and used for genomic analysis are identiﬁed. The table in the bottom right indicates speciﬁc assays used on
samples from each time point. Additional sample details can be found in supplementary Table S1, available at Annals of Oncology online. FOLFOX, 5-ﬂuorour-
acil, leucovorin, and oxaliplatin; R, right; L, left; SBRT, stereotactic body radiotherapy (Cyberknife™); IMRT, intensity modulated radiation therapy; DIBH,
deep inspiration breath hold.
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intermediate entity on a continuum, from pure FL-HCC to con-
ventional HCC.
Recent surveys of the genomic landscape of both conventional
HCC (predominantly hepatitis-associated) and pure FL-HCC
have differentiated the genomic proﬁles of these two subtypes.
Conventional HCC is characterized by recurrent point muta-
tions (including in TP53, CTNNB1, and TERT), HBV integra-
tion sites, structural variants, and copy number variants (CNVs)
affecting chromatin regulators and the TERT promoter, among
others [6–8]. Overall, FL-HCCs show fewer large-scale chromo-
somal alterations and less frequent methylation of tumor sup-
pressor promoters with methylation changes primarily near
liver developmental genes when compared with conventional
HCC [9–11]. Most notably, a novel DNAJB1:PRKACA fusion
has been identiﬁed in association with pure FL-HCC but not in
conventional HCC [9, 11–13]. Although methylation and RNA
expression proﬁling has been evaluated in a very small number
of mFL-HCC cases, no comprehensive genomic proﬁles of
mFL-HCC have been published.
results
Exome sequencing with custom capture probes also targeting
HBV, HCV and the TERT promoter region (supplementary
Table S2, available at Annals of Oncology online) produced cover-
age of 99.1% of targeted regions at a minimum 20× depth (mean
347×) for BrainMet1.1 DNA and 96.1% at 20× (mean 114×) for
BloodNorm DNA. Figure 3 depicts the key ﬁndings of exome and
transcriptome sequencing. No evidence of HCV or HBV expres-
sion or integration, or TERT promoter mutations was observed
(supplementary Figure S4, available at Annals of Oncology
online). Similar to previous reports for pure FL-HCC, a very low
somatic mutation rate was observed compared with the median of
45 nonsynonymous exome mutations (∼2 mutations/Mb) previ-
ously reported for conventional HCC [13, 14]. In fact, only two
somatic exome SNVs (TACC2, LOC81691) and zero indels were
unambiguously somatic variants. None of the previously reported,
recurrently mutated genes in HCC were mutated in this case, nor
were the few mutations observed obvious cancer-driving genes.
A high number of primarily single-copy, long-range CNVs
were observed (Figure 3), including previously described, recur-
rent deletions affecting chr 4q (q22.3–q35.2) and 22 as well as
ampliﬁcation of 19p [9]. RNA-sequencing data analysis identiﬁed
a large number of highly expressed cancer genes (top 2%) includ-
ing ERBB2 and EGFR. Immunohistochemistry determined that
the tumor was androgen receptor negative, ERBB2 score of 2+
and EGFR (membranous staining) intermediate at 2+. Note that
ERBB2 was highly expressed in this case as recently reported for
pure FL-HCC but not for other mixed FL-HCC [5].
Only three fusion transcripts were predicted by both
ChimeraScan and Integrate: DNAJB1:PRKACA, TTC33:PRKAA1,
and BCAS3:CLTC (supplementary Table S3A and B and Results,
available at Annals of Oncology online). By far the most highly
expressed fusion was DNAJB1:PRKACA (supplementary Appendix
1, available at Annals of Oncology online), the product of combin-
ing exon1 of DNAJB1 to exon2 of PRKACA in a head-to-tail
fashion (supplementary Figures S5 and S6, available at Annals of
Oncology online). The fusion appears to be upregulated and
expressed in an allele-speciﬁc manner (supplementary Results,
available at Annals of Oncology online). RT-PCR followed by se-
quencing of the ampliﬁed RNA products was used to validate the
predicted DNAJB1:PRKACA fusion (supplementary Table S4,
Figures S7–S9 and Methods and Results, available at Annals of
Oncology online). No evidence for the DNAJB1:PRKACA fusion
was identiﬁed in RNA-seq data from 30 conventional HCC cases
or 30 adjacent nontumor liver tissues.
To determine whether this fusion was unique to the ﬁbrola-
mellar components of this tumor, we extended our analysis to
additional samples from this individual (Figure 2, samples and
assays; supplementary Table S1, available at Annals of Oncology
online). This included bulk formalin-ﬁxed parafﬁn-embedded
samples from each nodule of the primary tumor with conven-
tional, mixed and ﬁbrolamellar HCC pathology and metastatic
sites (brain, lung, skin) with FL-HCC pathology. The presence
of the DNAJB1:PRKACA fusion was assayed using custom
Nanostring probes (nCounter Elements™ TagSets) speciﬁc to
the fusion (supplementary Table S5, available at Annals of
Oncology online). All primary tumor samples, regardless of
pathology, tested positive for the fusion. Of the metastatic sites,
only a single sample (LungMet1) was negative for the fusion.
This same RNA sample resulted in RT-PCR bands of unexpect-
ed size but upon sequencing showed evidence of the fusion.
Two additional RNA samples from this same metastatic site
(LungMet2-3) were evaluated and tested positive for the fusion
(supplementary Figure S10, available at Annals of Oncology
online). We repeated this experiment in a second individual
(Case2) with mFL-HCC that presented with ﬁbrolamellar HCC
and later developed a primary liver recurrence and lymph node
metastasis with conventional HCC pathology (supplementary
Information and Figure S11, available at Annals of Oncology
online). The fusion was readily detected in the lymph node metas-
tasis (Case2_LymphMet) with conventional HCC pathology but
not in the primary (Case2_Primary1-2) or liver recurrence
(Case2_LiverRec) samples. As no other conventional HCC
samples have tested positive for the fusion [9, 12, 13], the most
likely explanation is that the fusion was present in the ﬁbrola-
mellar primary and retained in the metastasis but that low avail-
able RNA quantities and poor sample quality from archival
tissue prevented detection. An additional 112 HCC samples and
44 adjacent matched normal tissues were also analyzed for the
presence of the fusion (supplementary Methods and Results,
Figure S10, available at Annals of Oncology online). A single
HCC sample, but no normal samples, tested positive for pres-
ence of the fusion. Evaluation of the pathology reports from this
sample indicated this tumor had regions of both ﬁbrolamellar
and conventional HCC consistent with mFL-HCC (Case3). No
additional samples (N = 111) had descriptions consistent with
mixed or pure FL-HCC upon review.
We used the comprehensive data available for the index
patient to further characterize the nature of the genomic alter-
ation leading to the DNAJB1:PRKACA fusion. Analysis of geno-
typing array data (BrainMet1.1) for the genomic region between
DNAJB1 and PRKACA revealed a focal-deletion of ∼400 kb on
chr19 (supplementary Figure S12, available at Annals of
Oncology online). The exact genomic breakpoints responsible
for the DNAJB1:PRKACA fusion were determined by a novel
custom capture-based sequencing approach. Three BAC clones
spanning the region from DNAJB1 to PRKACA were identiﬁed
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(supplementary Table S6, Figure S13 and Methods, available at
Annals of Oncology online), used to create a BAC-clone capture
reagent, and then captured libraries were sequenced either on
Illumina or Paciﬁc Biosciences instruments (supplementary
Figures S14–S18, Tables S7–S9, and Appendix 2, available at
Annals of Oncology online). Both methods supported a deletion
of 406 272 bases between the ﬁrst intron of DNAJB1 and ﬁrst
intron of PRKACA (chr19: 14 221 615–14 627 887, hg19) in the
BrainMet1.1 sample. Support for the fusion was also observed
for the LungMet1 sample (Illumina) but not for the BloodNorm
sample (either platform). PCR validation yielded products of the
expected size in all primary and metastatic (but not normal)
samples from the patient (supplementary Tables S10 and S11
and Figure S19, available at Annals of Oncology online). Analysis
of variant allele fractions in this region also revealed an expected
loss of heterozygosity event within the deletion breakpoints (sup-
plementary Figure S20, available at Annals of Oncology online).
As mentioned above, there was also evidence of ampliﬁcation
of the entire chr 19p arm (Figure 3). It is difﬁcult to know for
certain whether the focal-deletion occurred ﬁrst and then was
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Figure 3. ACircos plot displays genomic and transcriptomic alterations observed in the BrainMet1.1 sample from the index case of mixed ﬁbrolamellar HCC.
For the outermost ring, a chromosome ideogram is shown with selected genes labeled. The ﬁrst data track displays copy number variants (CNVs) from geno-
type array data with tumor-normal logR ratios plotted and segments called by cnv-hmm (unpublished software). Copy-altered segments are indicated as dark
red (gain) or dark blue (loss). The next data track plots RNA-seq gene-level fragments per kilobase of transcript per million mapped reads (FPKM) values on a
log2 scale in light green with the top 1% most highly expressed genes indicated in dark green. Next, single-nucleotide variants (black), small insertions (red),
and small deletions (blue) from exome data are indicated. These include two somatic and ﬁve ambiguous variants (supplementary Results, available at Annals
of Oncology online). Finally, the centermost ring plots RNA-seq fusions (ChimeraScan) in light blue with the intrachromosomal fusion between DNAJB1 and
PRKACA highlighted in red.
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subsequently ampliﬁed. However, this would be parsimonious
with an evolutionary process promoting further activation of
PRKACA. Recurrent 19p ampliﬁcations have been previously
reported in small comparative genomic hybridization studies of
pure FL-HCC [10]. More recently, Graham et al. observed aneu-
ploidy affecting the PRKACA locus, both involving the fusion
and the wild-type allele, in a large percentage of cells from pure
FL-HCC patients using ﬂuorescence in situ hybridization (FISH)
probes [12]. Taken together, the likely explanation for upregula-
tion of PRKACA is allele-speciﬁc expression driven by the
DNAJB1 promoter-swap and/or ampliﬁcation of the fusion allele.
Analysis of microarray data from Malouf et al. [5] for 39
HCCs (17 pure FL-HCC, 5 mixed, 7 noncirrhotic HCC, 10 adja-
cent livers) also demonstrated signiﬁcant upregulation of
PRKACA in pure FL compared with conventional HCC
(216234_s_at: P = 0.009; 202801_at: P = 2.31e−05) and normal
liver tissues (216234_s_at: P = 0.003; 202801_at: P = 2.3e−05;
supplementary Figure S21, available at Annals of Oncology
online). mFL-HCC expression levels for PRKACA were inter-
mediate and signiﬁcantly higher than conventional HCC for
one probe set (202801_at: P = 0.030) but not otherwise signiﬁ-
cantly different from other disease types. DNAJB1 was signiﬁ-
cantly down-regulated in pure FL compared with nontumor
liver tissues (200664_s_at: P = 0.005; 200666_s_at: P = 0.011;
supplementary Figure S22, available at Annals of Oncology
online). In general, DNAJB1 showed the inverse pattern of
PRKACA with the lowest DNAJB1 expression in pure FL-HCC,
followed by intermediate levels in mixed, and then progressively
higher levels in conventional and normal samples. Normal
RNA-seq data were not obtained from this mFL-HCC case for
direct comparison; however, the level of PRKACA expression
in the mFL-HCC was higher (3.97 standard deviations or 4.11-
fold) and a statistical outlier when compared with data from 30
conventional HCC samples (Grubb’s test, P = 3.56e−05) (sup-
plementary Figure S23, available at Annals of Oncology online).
DNAJB1 expression in the mFL-HCC was comparable with the
mean of the conventional HCC cases.
discussion
We present here the ﬁrst comprehensive exome and transcrip-
tome analysis of a mixed ﬁbrolamellar HCC (mFL-HCC). We
observed a remarkably low mutation rate with no strong cancer-
driving SNV or indel candidates consistent with previous
reports of pure FL-HCC [9, 13]. However, RNA-seq analysis
identiﬁed high expression of many cancer-relevant and poten-
tially druggable genes and the DNAJB1:PRKACA fusion. Shortly
after completion of our initial analysis, Honeyman et al. [13]
reported an identical chimeric RNA transcript in a cohort of
pure FL-HCC patients. Subsequent reports have independently
validated the high recurrence of this fusion in pure FL, but not
conventional, HCC [9, 11, 12, 15]. Consistent with our observa-
tions, Honeyman et al. reported the PRKACA transcript expres-
sion was signiﬁcantly upregulated in relation to normal tissue
[13]. Identiﬁcation of this fusion in mFL-HCC is important to
our understanding of the etiology of this HCC subtype.
A small body of literature suggests that mFL-HCC is a subtype
of disease clinically distinct from conventional HCC and pure FL-
HCC. However, in this case, it appears to share the recently
discovered and most important genetic feature of FL-HCC
reported to date and thus could be grouped together with FL-HCC
as a candidate for PRKACA targeted therapy (if one can be devel-
oped). FL-HCC and by extension mFL-HCC diagnosis remains
challenging [5]. This is especially true for cases in which the
disease occurs at an atypical age or in the context of underlying cir-
rhotic liver and is magniﬁed by tumor heterogeneity and poor re-
producibility of pathologic examination of primary liver tumors
with ﬁbrous stroma [16]. The studies referenced show that, while
FL-HCC had better interobserver reproducibility than other types
of HCC there was still substantial disagreement with a real possibil-
ity of both false-positive and false-negative diagnoses. A highly spe-
ciﬁc and easily detected event such as the DNAJB1:PRKACA fusion
could represent a much more accurate diagnostic tool.
Recent studies evaluating the presence of the DNAJB1:
PRKACA fusion in pure FL-HCC have reported detection in
79%–100% of samples [9, 11, 12]. One group also evaluated this
fusion in ﬁve cases of mFL-HCC but failed to identify this
fusion in any sample [11]. We not only identiﬁed the fusion in
all portions of the primary tumor, regardless of pathology, but
in all subsequent metastases studied in our initial mFL-HCC
patient. Expansion of this analysis to an additional patient with
temporally separated presentations of FL and conventional
HCC, conﬁrmed this ﬁnding. Finally, screening a large cohort
of HCC with a Nanostring assay identiﬁed a third case with
mixed ﬁbrolamellar characteristics. Graham et al. reported the
use of a FISH assay to identify the fusion in FL-HCC samples
that failed in their initial round of RT-PCR detection. Together
these studies indicate that more sensitive methods should be
considered when evaluating the presence of this fusion in both
mixed and pure FL-HCC [12]. Although more mFL-HCC
samples should be evaluated for this fusion, we present evidence
that it can be detected in at least a subset of these very rare cases.
The increased kinase activity observed as a result of the recur-
rent DNAJB1:PRKACA fusion presents the obvious strategy of
PRKACA inhibition as a potential treatment modality for both
mixed and pure FL-HCC [13]. A search for PRKACA-speciﬁc
inhibitors using the Drug-Gene Interaction Database (DGIdb)
[17] identiﬁed a small number of potential compounds;
however, they generally lack potency or speciﬁcity (supplemen-
tary Table S12A–E and Results, available at Annals of Oncology
online) [18]. Given the ﬁnding in this and other recent studies
of the likely importance of PRKACA activation in mixed and
pure FL-HCC, renewed efforts are warranted for the develop-
ment of inhibitors speciﬁc to PRKACA or perhaps the DNAJB1:
PRKACA fusion protein itself. Lacking speciﬁc inhibitors for
PRKACA, we considered other targets, potentially upregulated
by PRKACA activation by comparing expression levels in pure
FL versus conventional HCC and nontumor tissues as described
above. We identiﬁed ﬁve potentially druggable targets, including
ERBB2, one of the most highly expressed genes in the mFL-
HCC of this study (supplementary Results, Figure S24, and
Table S13, available at Annals of Oncology online). Drugs such
as lapatinib, which targets ERBB2, have good phase III safety
and efﬁcacy data in breast cancer. Lapatinib was investigated in
a phase II clinical trial in HCC and, although well tolerated, was
discontinued due to lack of efﬁcacy in advanced patients [19].
However, the status of ERBB2 overexpression was not evaluated
in that study and to our knowledge ERBB2 inhibitors have not
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been systematically evaluated in FL-HCC, the subtype most
associated with overexpression. In the index case for this study,
the patient favored palliative locoregional therapy and chose to
not pursue systemic therapy with limited data. This is likely to
be a common outcome of such genome-driven approaches. In
many cases, even highly relevant events such as the DNAJB1:
PRKACA fusion are not actionable, and other genomic events
are not sufﬁciently compelling to alter treatment decisions.
conclusion
This study extends the recent discovery of DNAJB1:PRKACA
fusions in pure ﬁbrolamellar HCC to mixed FL-HCC. It seems
likely that this highly recurrent and unique genomic and tran-
scriptomic event may be a useful diagnostic tool for distinguish-
ing pure and mixed FL-HCC from conventional HCC even
when ﬁbrolamellar characteristics are absent at pathology. We
also add to evidence that FL-HCC may be driven by structural
variants and fusion transcripts far more than SNVs/Indels. We
present a novel strategy for identifying DNA breakpoints in the
absence of whole-genome sequence data by using BAC-clone
DNA to create custom hybrid-capture reagents to enrich for and
sequence relatively large genomic regions. This approach repre-
sents a convenient strategy for discovery and validation of struc-
tural variations in small sample sets for large genomic regions
that are challenging for PCR validation but would not be cost-
effective for conventional capture-based approaches using com-
mercial probes. Similarly, the Nanostring Elements technology
represents a convenient and rapid approach for sensitive detec-
tion of fusions in large sample sets. While the DNAJB1:PRKACA
fusion certainly stood out as interesting in our initial analysis, it
was not deemed clinically actionable. Its likely importance as a
driving event was only illuminated upon publication of the
Honeyman et al. analysis of 11 FL-HCCs. This illustrates a key
challenge of personalized medicine in that individual tumor
genomes must be interpreted in the context of a constantly accu-
mulating literature. Finally, this case presents a reminder of how
far targeted therapeutics still have to go. PRKACA seems a clear
candidate for drug development. However, clinically useful inhibi-
tors remain elusive. Efforts should be redoubled given the new sig-
niﬁcance of this kinase in both mixed and pure ﬁbrolamellar HCC.
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